The Filing Desk

OmniAb

OABI · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

OABI · Last close · November 13, 2026
$4.91
Value OmniAb yourself

OmniAb's revenue fell 29.3% to $19 million in fiscal 2025. Its operating margin was −369.5%, down from −282.3% a year earlier. Free cash flow was −$37 million. The diluted share count rose 11.0%.

OMNIAB, INC. Latest fiscal year ended December 31, 2025 10-K filed March 4, 2026 · 0001846253-26-000009 Updated
Revenue
$19M
29.3%
Operating margin
−369.5%
87.2 pts
Net income
−$65M
 
Free cash flow
−$37M
 
Return on equity
−23.4%
2.8 pts
Market cap
$635M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What OmniAb does

OmniAb licenses antibody discovery technology to drug and biotech companies and to universities. Its platform uses genetically modified animals, including rats, chickens and mice, that make antibodies with human sequences, and it screens those antibodies one cell at a time to find candidates for its partners' drugs. It also offers computer tools and capabilities for ion channels and transporters, a hard class of drug targets.

It earns money under license agreements that generally include upfront or annual access fees, payments for research services, milestone payments and royalties on its partners' product sales. Academic partners typically share revenue instead. OmniAb says it expects milestones and services to drive revenue in the near term and royalties in the longer term, but says the timing of any drug approval is uncertain. It does not control how partners develop or sell the drugs.

At the end of 2025 it had 107 active partners with 407 active programs, including three approved products made by its partners.

Its biggest risks, as it describes them

  • Biotech drugs from its partners' programs may never reach the market, so milestone and royalty payments may not come.
  • Dependence on a limited number of partners for revenue, and on partners to report milestones and pay on time.
  • Its lack of control over its partners' clinical trials, regulatory plans and sales efforts.
  • Competition in antibody discovery technology, and fast technology change.
  • Reliance on animal colonies, some hosted by third parties, that could suffer disease or public controversy.
From OmniAb's annual report on Form 10-K, filed March 4, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

OmniAb lost money in fiscal 2025: a net loss of $65 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments088875954
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−5,087.0x————
Current ratio1.1x4.8x4.1x4.5x4.0x
Quick ratio1.1x4.8x4.1x4.5x4.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project OmniAb's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of OmniAb reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−40.1%−180.2%−227.6%
Altman Z''5.126.486.00
Accruals ratio−13.3%−6.4%−9.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put OmniAb side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
OmniAbFY25−29.3%−369.5%−198.3%———
PersonalisFY25−17.7%−126.4%−114.1%———Compare
PacBioFY253.9%−346.1%−71.2%−77.1%—3Compare
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———Compare
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue3559342619
Revenue growth—70.0%−42.2%−22.8%−29.3%
Gross profit—————
Research and development3948565548
Operating income−36−27−69−74−69
Net income−27−22−51−62−65
Diluted EPS (US$)−0.33−0.26−0.51−0.61−0.57
Diluted shares (millions)8385100102114
Cash flow
Cash from operations−6−42−40−36
Capital expenditure417221
Free cash flow−10−211−42−37
Dividends paid00000
Share buybacks00000
Acquisitions00000
Stock-based compensation1518252216
Balance sheet at fiscal year end
Cash and short-term investments088875954
Debt incl. finance leases—————
Total assets304421375326301
Total liabilities7080613834
Shareholders' equity234341315288267
Margins and ratios
Gross margin—————
Operating margin−102.5%−45.1%−203.2%−282.3%−369.5%
Net margin−77.8%−37.8%−148.2%−235.1%−347.0%
Free cash flow margin−28.0%−35.1%2.1%−157.4%−198.3%
Rule of 40 (growth + FCF margin)—34.9%−40.1%−180.2%−227.6%
Return on capital—————
Return on equity—−7.8%−15.4%−20.6%−23.4%
Return on assets—−6.2%−12.7%−17.7%−20.7%
Net debt to EBITDA—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: OmniAb's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with OmniAb.